OHR Pharmaceutical

Ohr Pharmaceutical, founded in 2009, was a clinical-stage pharmaceutical company focused on developing novel therapeutics for ophthalmic diseases. The company's lead product candidate was Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), a topical eye drop formulation intended for the treatment of neovascular, or 'wet', age-related macular degeneration (wet AMD). This product was designed as a non-invasive, self-administered adjunct therapy to potentially reduce or eliminate the need for intravitreal injections, the standard of care.

The company advanced Squalamine into Phase 3 clinical trials following a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA), which also granted the program Fast Track designation. However, after facing challenges in its clinical development program, including pausing trial enrollment for strategic reasons, Ohr began a comprehensive review of strategic alternatives. This process culminated in a definitive merger agreement with NeuBase Therapeutics, Inc., which was announced in January 2019 and completed in July 2019. The transaction was a reverse merger, resulting in Ohr stockholders owning approximately 20% of the combined entity, with NeuBase stockholders holding the majority 80%. Following the merger, the company was renamed NeuBase Therapeutics, Inc., changed its Nasdaq ticker symbol from "OHRP" to "NBSE," and shifted its focus to NeuBase's proprietary PATrOL™ technology platform for developing gene-silencing therapies for rare genetic diseases like Huntington's disease and myotonic dystrophy. The new entity's headquarters were established in Pittsburgh, PA, under the leadership of NeuBase's executive team.

Keywords: Ohr Pharmaceutical, NeuBase Therapeutics, reverse merger, ophthalmology, wet AMD, Squalamine, OHR-102, clinical trials, gene silencing, rare genetic diseases, drug development, biotechnology, macular degeneration, ocular disease, anti-angiogenic